Step 1 topics → Hematology and Oncology → Antiphospholipid Syndrome

Antiphospholipid Syndrome

USMLE Step 1 trap: Interprets the prolonged PTT in APS as a bleeding risk rather than recognizing the in vitro artifact masking in vivo thrombophilia. In APS, antiphospholipid antibodies prolong PTT in vitro by interfering with the phospholipid surface used in the assay, but in vivo they block natural anticoagulants causing thrombosis.

Antiphospholipid syndrome (APS) is a hypercoagulable state driven by autoantibodies — anticardiolipin, anti-beta-2 glycoprotein I, and lupus anticoagulant — that paradoxically cause thrombosis despite prolonging the PTT. It shows up in USMLE Step 1 as a clinical vignette involving recurrent miscarriages, unexplained arterial or venous thrombosis (especially in a young woman with or without lupus), or a lab panel showing a prolonged PTT that doesn't correct with mixing. The exam wants you to connect the dots between the lab findings, the mechanism, and the treatment — and it specifically sets traps around the PTT result.

The central trick is the PTT paradox: a prolonged PTT usually signals bleeding risk, but in APS it signals thrombosis risk. Students who don't understand why it's prolonged get this wrong every time. The antibodies interfere with the phospholipid reagent used in the in vitro PTT assay, making it look like there's a clotting factor deficiency. In vivo, these same antibodies disrupt natural anticoagulant pathways, tipping the balance toward clot formation. USMLE Step 1 also tests the target antigen question — the antibodies aren't going after phospholipids directly, they're targeting phospholipid-binding proteins like beta-2 glycoprotein I.

The management angle is tested in two contexts: standard APS (long-term warfarin) and pregnancy-related APS (warfarin is off the table because it's teratogenic). Confusing these two scenarios is one of the most common errors on this topic. Knowing the diagnostic criteria — antibodies must be present on two occasions at least 12 weeks apart, plus a clinical event — is also fair game for Step 1 passage-based questions.

From real student decks
68%have cards covering this topic
65%have mature cards

Common misconceptions

Common mistake
Wrong: The prolonged PTT in APS means patients are at risk for bleeding.
Right: In APS, antiphospholipid antibodies prolong PTT in vitro by interfering with the phospholipid surface used in the assay, but in vivo they block natural anticoagulants causing thrombosis.
A prolonged PTT usually means impaired clot formation and bleeding risk — but APS is the exception that proves the rule. The PTT assay depends on an exogenous phospholipid surface to activate clotting factors in the test tube; antiphospholipid antibodies bind that reagent and slow the reaction artificially. In the patient's body, those same antibodies actually inhibit natural anticoagulants (like protein C activation and annexin V binding), so the net in vivo effect is clotting, not bleeding. When you see a prolonged PTT that doesn't correct with mixing plus a clinical history of thrombosis or miscarriage, think APS — not hemophilia.
Common mistake
Wrong: Warfarin is the preferred anticoagulant for APS in pregnancy.
Right: Warfarin is teratogenic and contraindicated in pregnancy; APS in pregnancy is managed with low-molecular-weight heparin plus low-dose aspirin.
Warfarin crosses the placenta and is teratogenic — it causes warfarin embryopathy (nasal hypoplasia, stippled epiphyses) in the first trimester and fetal bleeding later. For APS in pregnancy, the correct regimen is low-molecular-weight heparin (which does not cross the placenta) combined with low-dose aspirin to reduce thrombotic risk and improve fetal outcomes. This is a high-yield distinction on USMLE Step 1: warfarin is the right answer for non-pregnant APS patients, but the moment the question introduces pregnancy, switch your answer to LMWH plus aspirin.
Common mistake
Wrong: Antiphospholipid antibodies directly target phospholipids on cell membranes.
Right: Antiphospholipid antibodies primarily target phospholipid-binding proteins, especially beta-2 glycoprotein I and prothrombin, not bare phospholipids directly.
Despite the name 'antiphospholipid,' these antibodies don't bind naked phospholipids directly — they require a protein intermediary. The dominant target is beta-2 glycoprotein I (beta-2 GPI), a plasma protein that binds anionic phospholipids; antibodies against beta-2 GPI bound to cardiolipin are what the anticardiolipin assay detects. Understanding this matters because it explains the false-positive VDRL: the VDRL test uses cardiolipin as antigen, and APS antibodies cross-react with it even though the patient has never had syphilis. It also explains why anti-beta-2 GPI antibodies are the most specific serologic marker for APS.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Identify the actual molecular targets of antiphospholipid antibodies (beta-2 glycoprotein I and prothrombin, not bare phospholipids) and explain how this leads to thrombosis rather than bleeding.
  2. Interpret a prolonged PTT that does not correct on mixing study in the context of APS — recognizing it as an in vitro artifact caused by interference with the phospholipid reagent, not a true factor deficiency causing bleeding risk.
  3. Select the correct anticoagulation strategy for APS depending on whether the patient is pregnant (LMWH plus low-dose aspirin) or not pregnant (long-term warfarin), and explain why warfarin is contraindicated in pregnancy.

Can you avoid these mistakes?

A 28-year-old woman with SLE has had two unexplained second-trimester fetal losses. Her PTT is 58 seconds and does not correct with a 1:1 mixing study. What is the most likely diagnosis, and what does the non-correcting PTT tell you about her bleeding vs. thrombosis risk?
On her serology workup, the same patient tests positive for anticardiolipin antibodies. Her RPR also comes back weakly positive, but a confirmatory FTA-ABS is negative. Why is her RPR positive, and what does this false-positive test reflect about the actual target antigen in APS?
You confirm APS in a 32-year-old woman who is now 8 weeks pregnant. She asks whether she should restart the warfarin she was taking before conception. What do you tell her, and what regimen do you prescribe instead?
A question stem describes a patient with recurrent DVTs, a prolonged PTT, and thrombocytopenia. The laboratory reports that the PTT does not correct with mixing. Which antibody test(s) would you order to confirm the diagnosis, and what two clinical or serologic criteria must be met before diagnosing APS?

Related topics

Coagulation Cascade and PT/PTT Interpretation Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →